FAP and malignant colon neoplasm: The colored area in Figure 5 represents scenarios where at least 50% of the maximum pharmacological effect is predicted to be achieved as a function of FAP-binding affinity and bispecific antibody concentration for the typical colon cancer FAP expression (2,960 FAP/fibroblast).